Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024
Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
- Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
- ECCMID is taking place online and in-person in Barcelona, Spain from April 27-30, 2024.
- Longhorn’s vaccine and antibody product candidates focus on rapidly mutating viruses that include influenza, coronavirus, and antimicrobial resistant pathogens.
- “We are very excited to present the first data from our universal influenza vaccine in pigs,” said Jeff Fischer, President Longhorn Vaccines and Diagnostics.